Semaglutide medications including Ozempic and Wegovy have been shown to reduce kidney failure risk and the risk of death among people with kidney disease and type 2 diabetes. Two doctors weighed in.
Semaglutide medications — including Ozempic and Wegovy — have been shown to reduce the risk of kidney failure and the risk of death among people with kidney disease and type 2 diabetes. In a trial led by UNSW Sydney between June 2019 and May 2021, researchers found that a small weekly dose of semaglutide lessened the likelihood of 'major kidney events' by 24%, according to a press release.
The participants received 1.0 mg per week of semaglutide, which is less than what is typically prescribed for weight loss or diabetes, the release noted. The median follow-up was 3.4 years. 'It’s the same chemical compound, but we used a lower dose ... we did that deliberately because people with kidney disease tend to be more sensitive to the effects and side effects of drugs,' said the study’s lead author, professor Vlado Perkovic of UNSW Sydney, in the release.
This lifesaving result is likely due to the metabolic effects of the drug, which helps with reducing inflammation, overcoming insulin resistance, and improving insulin function and glucose metabolism at the cellular level,' Siegel told Fox News Digital. 'This study has broader implications for all patients who have kidney failure.' 'Improved kidney function means improved heart function, and pressure on the heart from failed kidneys is a major cause of heart attack and death.
The challenge is to get these results into clinical practice, to get the drug used by the people who will benefit from it, who will live longer without dialysis, without heart attacks, without strokes, if they take this drug,' Perkovic said. For more Health articles, visit www.foxnews.com/health.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic Drug Semaglutide Could Protect Kidneys, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Forget Ozempic and Wegovy — Utahns embracing natural solution to boost GLP-1Given the potential side effects of GLP-1 prescription drugs, many Utahns are seeking alternative methods to naturally boost GLP-1 levels in the body.
Read more »
– Young Adults’ Use of Popular Weight Loss Drugs Wegovy and Ozempic Skyrockets by 594%Science, Space and Technology News 2024
Read more »
Use of weight-loss drugs Wegovy and Ozempic climbs among childrenThe use of weight-loss drugs such as Wegovy and Ozempic has climbed among children in the United States, according to a study released Wednesday.
Read more »